NIIMBL will develop a testbed to support the Vaccine Analytics and Assays Center of Excellence. The testbed will include relevant technology / instruments from small to medium manufacturers (SMMs), (e.g., already identified within NIIMBL and leveraging from prior NIIMBL investments).
It will also include supporting infrastructure around cell culture needed to support cell-based potency and stability assays that can help bridge between animal-based tests, as well as create new higher throughput in vitro tests to address many issues across a range of vaccine modalities.
The project will enable unprecedented collaboration opportunities for vaccine innovators, SMMs and academics to converge on key techniques and fill gaps for making coronavirus vaccines more quickly and widely available to a broad US population.
The facility and equipment will be available for NIIMBL members to assess techniques and facilitate training and knowledge for implementation on a company-by-company basis that will positively impact the overall US preparedness and response to future pandemics.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.